{"filing":{"accession_number":"0001193125-26-245181","cik":"0001162194","ticker":"LAB","company_name":"STANDARD BIOTOOLS INC.","form":"8-K","filing_date":"2026-05-28","report_date":null,"primary_document":"lab-20260521.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1162194/000119312526245181/lab-20260521.htm"},"events":[{"id":8428,"run_id":7395,"accession_number":"0001193125-26-245181","anchor_item_number":"5.02","event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"The filing discloses Board approval of two severance and change-of-control plans (the 2026 and 2023 Severance Plans) and execution of participation agreements by named executives Alex Kim (CFO), Sean Mackay (Chief Business Officer), and Michael Egholm (CEO). These arrangements establish compensatory benefits—including cash severance multiples (100–250% of base salary plus bonus), equity acceleration, and health coverage continuation—triggered upon qualifying terminations. This is a material disclosure of compensatory arrangements for directors and officers under Item 5.02(e).","company_name":"STANDARD BIOTOOLS INC.","ticker":"LAB","filing_date":"2026-05-28","form":"8-K","submitted_at":null,"items":[{"id":2313,"accession_number":"0001193125-26-245181","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses Board approval of two severance and change-of-control plans (the 2026 and 2023 Severance Plans) and execution of participation agreements by named executives Alex Kim (CFO), Sean Mackay (Chief Business Officer), and Michael Egholm (CEO). These arrangements establish compensatory benefits—including cash severance multiples (100–250% of base salary plus bonus), equity acceleration, and health coverage continuation—triggered upon qualifying terminations. This is a material disclosure of compensatory arrangements for directors and officers under Item 5.02(e).","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-29T02:21:51.926265+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":2313,"accession_number":"0001193125-26-245181","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses Board approval of two severance and change-of-control plans (the 2026 and 2023 Severance Plans) and execution of participation agreements by named executives Alex Kim (CFO), Sean Mackay (Chief Business Officer), and Michael Egholm (CEO). These arrangements establish compensatory benefits—including cash severance multiples (100–250% of base salary plus bonus), equity acceleration, and health coverage continuation—triggered upon qualifying terminations. This is a material disclosure of compensatory arrangements for directors and officers under Item 5.02(e).","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-29T02:21:51.926265+00:00","company_name":"STANDARD BIOTOOLS INC.","ticker":"LAB","filing_date":"2026-05-28"}]}